Medroxyprogesterone Acetate

Summary

Medroxyprogesterone Acetate (CHEMBL717) is an approved small-molecule female contraceptive drug (ATC L02AB02); indicated across 34 conditions including endometriosis and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L02AB02 (+2 more)
• Indications: 34 conditions
• Clinical trials: 73
• Chemistry: 386.5 Da · C24H34O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL717
Name	Medroxyprogesterone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6279
ChEBI	CHEBI:6716
ATC	L02AB02, G03AC06, G03DA02
Molecular formula	C24H34O4
Molecular weight	386.5
InChIKey	PSGAAPLEWMOORI-PEINSRQWSA-N

SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C

IUPAC name: [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate

ChEBI definition: An acetate ester resulting from the formal condensation of the 17α-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control.

Pharmacological roles (ChEBI): progestin, androgen, female contraceptive drug, synthetic oral contraceptive, adjuvant, inhibitor, antioxidant, antineoplastic agent.

Also known as: Adgyn medro, Amen, Climanor, Curretab, Cycrin, Depo-progevera, Depo-provera, Depo-provera oncology, Depo-subq provera 104, Depot-medroxyprogesterone acetate, Farlutal, Farlutal 100

Patent coverage: 13,467 distinct patent families (51,452 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Prelamin-A/C, ATP-binding cassette sub-family C member 4, Androgen receptor, Histamine H2 receptor, Mineralocorticoid receptor, Glucocorticoid receptor, Progesterone receptor, Estrogen receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 74 potent at pChembl ≥ 5 of 86 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	10	EC50	0.1	nM	CHEMBL_ACT_299910
PGR	9.92	EC50	0.12	nM	CHEMBL_ACT_299913
PGR	9.92	EC50	0.12	nM	CHEMBL_ACT_417776
PGR	9.82	EC50	0.15	nM	CHEMBL_ACT_1211170
PGR	9.82	EC50	0.15	nM	CHEMBL_ACT_228557
PGR	9.82	EC50	0.15	nM	CHEMBL_ACT_48433
PGR	9.82	EC50	0.15	nM	CHEMBL_ACT_619048
PGR	9.82	EC50	0.15	nM	CHEMBL_ACT_695331
PGR	9.82	EC50	0.15	nM	CHEMBL_ACT_828769
PGR	9.48	EC50	0.33	nM	CHEMBL_ACT_228562
PGR	9.48	EC50	0.33	nM	CHEMBL_ACT_48435
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_1211173
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_1734223
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_228558
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_48436
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_619051
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_695333
PGR	9.47	Ki	0.34	nM	CHEMBL_ACT_828772
PGR	9.4	EC50	0.4	nM	CHEMBL_ACT_2448993
PGR	9.3	EC50	0.5	nM	CHEMBL_ACT_1278208
PGR	9.3	EC50	0.5	nM	CHEMBL_ACT_2448978
PGR	9.3	EC50	0.5	nM	CHEMBL_ACT_369874
AR	9	Kd	1	nM	CHEMBL_ACT_24824131
PGR	8.85	Ki	1.4	nM	CHEMBL_ACT_2449034
AR	8.54	Ki	2.9	nM	CHEMBL_ACT_1211182
AR	8.54	Ki	2.9	nM	CHEMBL_ACT_228559
AR	8.54	Ki	2.9	nM	CHEMBL_ACT_48437
AR	8.54	Ki	2.9	nM	CHEMBL_ACT_619052
AR	8.54	Ki	2.9	nM	CHEMBL_ACT_828773
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204426

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

34 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
endometriosis	4	MONDO:0005133	EFO:0001065
neoplasm	4	MONDO:0005070	EFO:0000616
renal cell carcinoma	4	MONDO:0005086	EFO:0000681
hyperplasia	4	MONDO:0005043	EFO:0000536
renal carcinoma	4	MONDO:0005206	EFO:0002890
infertility disorder	3	MONDO:0005047	EFO:0000545
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673
coronary artery disorder	3	MONDO:0005010	EFO:0001645
heart disorder	3	MONDO:0005267	EFO:0003777
osteoporosis	3	MONDO:0005298	EFO:0003882
diabetes mellitus	3	MONDO:0005015	EFO:0000400
hypertensive disorder	3	MONDO:0005044	EFO:0000537
myocardial ischemia	3	MONDO:0024644	EFO:1001375
thrombotic disease	3	MONDO:0000831	MONDO:0000831
kidney cancer	3	MONDO:0002367	MONDO:0002367
endometrium neoplasm	3	MONDO:0021251	MONDO:0011962
Turner syndrome	3	MONDO:0019499	MONDO:0019499
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
bone disorder	3	MONDO:0005381	EFO:0004260
sleep apnea syndrome	2	MONDO:0005296	EFO:0003877
HIV infectious disease	2	MONDO:0005109	EFO:0000180
primary ovarian failure	2	MONDO:0005387	HP:0008209
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
breast neoplasm	2	MONDO:0021100	MONDO:0007254

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 73.

Phase distribution

Phase	Trials
PHASE3	19
Not specified	15
PHASE2	14
PHASE4	11
PHASE1	7
PHASE2/PHASE3	5
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06637189	PHASE4	NOT_YET_RECRUITING	Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.
NCT01074892	PHASE4	COMPLETED	A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia
NCT01148420	PHASE4	COMPLETED	DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
NCT01776203	PHASE4	TERMINATED	Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist
NCT01822288	PHASE4	COMPLETED	The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder
NCT02340013	PHASE4	COMPLETED	Endometrial Shedding Prior to Ovulation Induction Pilot Study
NCT02872818	PHASE4	COMPLETED	Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
NCT03034057	PHASE4	COMPLETED	Sayana Press UK Self-Injection Study
NCT03309176	PHASE4	COMPLETED	Stair Step Study
NCT04654741	PHASE4	UNKNOWN	The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles
NCT05651282	PHASE4	COMPLETED	Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
NCT05255653	PHASE2/PHASE3	RECRUITING	Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT06904274	PHASE3	RECRUITING	Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
NCT07124195	PHASE3	NOT_YET_RECRUITING	Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
NCT07319429	PHASE2/PHASE3	RECRUITING	Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
NCT00000419	PHASE3	TERMINATED	Safety of Estrogens in Lupus: Hormone Replacement Therapy
NCT00000466	PHASE3	COMPLETED	Postmenopausal Estrogen/Progestin Interventions (PEPI)
NCT00000559	PHASE3	COMPLETED	Women’s Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)
NCT00000605	PHASE3	COMPLETED	Estrogen and Graft Atherosclerosis Research Trial (EAGER)
NCT00002920	PHASE3	COMPLETED	S9630, Medroxyprogesterone in Treating Women With Breast Cancer
NCT00004650	PHASE3	COMPLETED	Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
NCT00026286	PHASE3	COMPLETED	Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
NCT00030914	PHASE3	COMPLETED	Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
NCT00066157	PHASE2/PHASE3	COMPLETED	Alzheimer’s Disease: Therapeutic Potential of Estrogen
NCT00083824	PHASE2/PHASE3	COMPLETED	Estrogen, HDL, and Coronary Heart Disease in Women
NCT00191113	PHASE3	COMPLETED	Somatropin Treatment to Final Height in Turner Syndrome
NCT00291369	PHASE3	COMPLETED	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
NCT00360490	PHASE3	COMPLETED	Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
NCT00416429	PHASE3	COMPLETED	Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
NCT01011751	PHASE3	COMPLETED	Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
NCT01472315	PHASE2/PHASE3	COMPLETED	Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities
NCT02103764	PHASE3	UNKNOWN	Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB
NCT02943655	PHASE3	COMPLETED	Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause
NCT03300960	PHASE3	COMPLETED	Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation
NCT03675139	PHASE3	COMPLETED	MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
NCT05247268	PHASE2	RECRUITING	Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
NCT05675787	PHASE2	RECRUITING	Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
NCT06979596	PHASE2	RECRUITING	A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT00003179	PHASE2	TERMINATED	Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
NCT00033358	PHASE2	COMPLETED	Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).